ARTICLES BY LOUIS GARGUILO
-
![Garguilo_Photo_2015]( "Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance")
Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance2/5/2015Just days after Outsourced Pharma’s in-depth, two-part article on Hospira and the role of biosimilars in global healthcare, and in which I asked Hospira’s Sumant Ramachandra whether he foresaw a future where a Pfizer comes to Hospira to work together on biosimilars, we have a definitive answer.
-
![Biosimilars Part 2: It’s All About Dollars Now]( "Biosimilars Part 2: It's All About Dollars Now")
Biosimilars Part 2: It's All About Dollars Now2/2/2015Time to table the discussion on the science of replicating biologics. It’s all about dollars now. Part two of our look at biosimilars in the U.S.
-
![Biosimilars: A Brief Manifesto of Morality And Markets]( "Biosimilars: A Brief Manifesto of Morality And Markets")
Biosimilars: A Brief Manifesto of Morality And Markets1/26/2015As best I can describe it, here's an ideology for biosimilars in the U.S. healthcare system, from Sumant Ramachandra, executive and scientist at Hospira, Inc.
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.